<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MIRTAZAPINE <img border="0" src="../images/pr.gif"/></span><br/>(mir-taz'a-peen)<br/><span class="topboxtradename">Remeron, </span><span class="topboxtradename">Remeron SolTab<br/></span><b>Classifications:</b> <span class="classification">central nervous system (cns) agent</span>; <span class="classification">psychotherapeutic agent</span>; <span class="classification">antidepressant, tetracyclic</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>15 mg, 30 mg, 45 mg tablets and orally disintegrating tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Tetracyclic antidepressant pharmacologically and therapeutically similar to the tricyclic antidepressants. Tetracyclics enhance
         central nonadrenergic and serotonergic activity; thought to be due to normalizing of neurotransmission efficacy. Mirtazapine
         is a potent antagonist of 5-HT<sub>2</sub> and 5-HT<sub>3</sub> serotonin receptors.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Acts as antidepressant. Effectiveness is indicated by mood elevation.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of depression.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to mirtazapine or mianserin; hypersensitivity to other antidepressants (e.g., tricyclic antidepressants and
         <small>MAOI</small> depressants), acute MI; fever, infection; agranulocytosis, neutropenia, hematologic disease; suicidal ideation; jaundice,
         ethanol intoxication; pregnancy (category C), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of cardiovascular or GI disorders; BPH, urinary retention; narrow-angle glaucoma, increased intraocular pressure;
         hepatic or renal impairment, renal failure; hypercholesterolemia, hypertriglyceridemia, thrombocytopenia; older adults; angina,
         cardiac arrhythmias, anticholinergic medications; bipolar disorder, mania, bone marrow suppression, PKU, history of MI; cerebrovascular
         disease, seizure disorder, seizures, stroke; depression; hypovolemia, surgery; closed-angle glaucoma; ileus, GI obstruction,
         dehydration; diabetes mellitus, diabetic ketoacidosis. Safety and effectiveness in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Depression</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 15 mg/d in single dose h.s., may increase q12wk (max: 45 mg/d)<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> use lower doses<br/><br/><span class="impairmenttitle">Renal or Hepatic Impairment</span><br/>Use lower doses<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give preferably prior to sleep to minimize injury potential.</li>
<li>Begin drug no sooner than 14 d after discontinuation of an MAO inhibitor.</li>
<li>Reduce dosage as warranted with severe renal or hepatic impairment and in older adults.</li>
<li>Store at 20°25° C (68°77° F) in tight, light-resistant container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Asthenia, flu syndrome, back pain, general and peripheral edema, malaise. <span class="typehead">CNS:</span> <span class="speceff-common">Somnolence,</span> dizziness, abnormal dreams, abnormal thinking, tremor, confusion, depression, agitation, vertigo, twitching. <span class="typehead">CV:</span> Hypertension, vasodilation. <span class="typehead">GI:</span> Nausea, vomiting, abdominal pain, <span class="speceff-common">increased appetite</span>/weight gain, <span class="speceff-common">dry mouth, constipation,</span> anorexia, cholecystitis, stomatitis, colitis, abnormal liver function tests. <span class="typehead">Respiratory:</span> Dyspnea, cough, sinusitis. <span class="typehead">Skin:</span> Pruritus, rash. <span class="typehead">Urogenital:</span> Urinary frequency. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Additive cognitive and motor impairment with <b>alcohol</b> or <span class="classification">benzodiazepines</span>; increase risk of hypertensive crisis with <span class="classification">maoi</span>s. <span class="typehead"> Herbal:</span> <b>Kava-kava,</b> <b>valerian</b> may potentiate sedative effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract, 50% reaches systemic circulation. <span class="typehead">Peak:</span> 2 h. <span class="typehead">Distribution:</span> 85% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver by cytochrome P450 system (CYP2D6, CYP1A2, CYP3A). <span class="typehead">Elimination:</span> 75% excreted in urine, 15% in feces. <span class="typehead">Half-Life:</span> 2040 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor WBC count with differential, lipid profile, and ALT/AST periodically.</li>
<li>Patients should be monitored for worsening of depression or emergence of suicidality.</li>
<li>Assess for weight gain and excessive somnolence or dizziness.</li>
<li>Monitor for orthostatic hypotension with a history of cardiovascular or cerebrovascular disease. Periodically monitor ECG
            especially in those with known cardiovascular disease.
         </li>
<li>Monitor those with a history of increased intraocular pressure or urinary retention carefully for worsening or recurrence.</li>
<li>Monitor those with history of seizures for lowering of the seizure threshold.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Do not use alcohol while taking drug.</li>
<li>Report immediately unexplained fever or S&amp;S of infection, especially flu-like symptoms, to physician.</li>
<li>Do not take other prescription or OTC drugs without consulting physician.</li>
<li>Make position changes slowly especially from lying or sitting to standing. Report dizziness, palpitations, and fainting.</li>
<li>Notify (women) physician immediately if you become pregnant.</li>
<li>Monitor weight periodically and report significant weight gains.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>